Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

United Therapeutic (NQ: UTHR )

374.02 +0.05 (+0.01%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 426,943
Open 375.78
Bid (Size) 314.00 (1)
Ask (Size) 379.60 (2)
Prev. Close 373.97
Today's Range 370.38 - 377.93
52wk Range 208.62 - 377.93
Shares Outstanding 44,891,523
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
United Therapeutics Corporation Reports Third Quarter 2024 Financial Results
From United Therapeutics Corporation
Via Business Wire
Earnings Outlook For United Therapeutics
Via Benzinga

Performance

YTD
+64.51%
+64.51%
1 Month
+6.11%
+6.11%
3 Month
+14.14%
+14.14%
6 Month
+42.54%
+42.54%
1 Year
+63.91%
+63.91%

More News

Read More
United Therapeutics Corporation Announces the 500th Lung Transplant Utilizing its Centralized Ex Vivo Lung Perfusion Service
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation to Report Third Quarter 2024 Financial Results Before the Market Opens on Wednesday, October 30, 2024
From United Therapeutics Corporation
Via Business Wire
Decoding 7 Analyst Evaluations For United Therapeutics
Via Benzinga
The Analyst Landscape: 7 Takes On United Therapeutics
Via Benzinga
$100 Invested In United Therapeutics 5 Years Ago Would Be Worth This Much Today
Via Benzinga
Peering Into United Therapeutics's Recent Short Interest
Via Benzinga
Amphastar Casts Wide Net, Hauls In Profits, Gets Rating Upgrade
Via Investor's Business Daily
Alkermes Stock Jumps Nearly 30% In 3 Months Amid Hefty Profits
Via Investor's Business Daily
A Look Into United Therapeutics Inc's Price Over Earnings
Via Benzinga
U.S. Stock: United Therapeutics Corp
Via Talk Markets
Here's How Much $1000 Invested In United Therapeutics 5 Years Ago Would Be Worth Today
Via Benzinga
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the CHEST 2024 Annual Meeting
From United Therapeutics Corporation
Via Business Wire
Key Takeaways From United Therapeutics Analyst Ratings
Via Benzinga
The Analyst Verdict: United Therapeutics In The Eyes Of 8 Experts
Via Benzinga
United Therapeutics Publishes its 2024 Corporate Responsibility and Public Benefit Report Highlighting its Progress Toward a Future Where No Patient Gets Left Behind—Ever
From United Therapeutics Corporation
Via Business Wire
FDA Battles Backlog of Drug Factory Inspections Since COVID-19
Via Benzinga
Exposures Product Safety
Keros Therapeutics Stock Meets 80-Plus RS Rating Benchmark
Via Investor's Business Daily
Innovative Drugmaker Roivant Puts Up Really Healthy Sales Numbers
Via Investor's Business Daily
Ambarella To Rally Around 61%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
United Therapeutics Corporation to Present at Upcoming Investor Conferences
From United Therapeutics Corporation
Via Business Wire
Biohaven Stock Earns Relative Strength Rating Upgrade
Via Investor's Business Daily
SpringWorks Therapeutics Stock Clears Key Benchmark, Hitting 80-Plus RS Rating
Via Investor's Business Daily
Soviet Code Breaker Jim Simons' Hedge Fund Renaissance Technologies — Ozempic, Wegovy Maker Novo Nordisk Along With Nvidia, Palantir Among Top Holdings
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.